DRKS00021474招募中不适用
Prevention of cerebral lesions by improving the management of postnatal hypoglycemia and hyperinsulinism - PRO-BRAI
niversitätsklinikum Düsseldorf0 个研究点目标入组 200 人开始时间: 2020年4月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0 Years 至 17 Years(—)
- 性别
- All
入选标准
- •Age at inclusion 0-17 years, age at diagnosis 0-48 months, inclusion period, i.e. Diagnoses within the past 10 years. At least one hypoglycemic event <45 mg / dl (2.6mmol/l). Diagnostic criteria for persistent congenital hyperinsulinism are based on established diagnostic criteria, i.e. in the first year of life: a significantly high carbohydrate requirement of >10mg/kg/min as well as hypoketotic, hyperinsulinemic hypoglycemia, which persist beyond the sixth month of life.
- •Diagnostic criteria for the investigation group transient hyperinsulinism are above all an increased glucose requirement of >10 mg/kg/min. Hypoketotic, hyperinsulinemic hypoglycemia confirm the diagnosis, but are not mandatory as the corresponding hormones/metabolites are not always measured. Other mandatory criteria are: initiation of drug therapy or persistence of hypoglycemia and need for treatment longer than the first 10 days of life and up to the sixth month of life. This means that an euglycemic metabolic state (without drug therapy) is required from the sixth month of life.
- •Diagnostic criteria for the transient neonatal hypoglycaemia are a persistent hypoglycaemia (<60 mg/dl) over the 72nd hour of life and <10 days. Diagnostic criteria of the physiological neonatal hypoglycaemia” investigation group include a spontaneous normalization of low blood sugars levels within the first 3 days of life.
排除标准
- •Prematurity <34th week of gestation;
- •Other severe disease at birth (e.g. severe heart defect, complex or severe underlying disease), syndromic hyperinsulinism forms, which affect the neurological development independently of hypoglycaemia.
- •Lack of consent from parents / patients.
- •The patient data of patients with persistent or transient hyperinsulinism are collected from the patient files at hospitals and clinics in Germany. Data from the entire first year of life are examined. The data of the patients in the control groups physiological neonatal hypoglycaemia and transitory neonatal hypoglycaemia are collected exclusively at the University Hospital in Düsseldorf. The patient data derives from 01/2008 - 12/2018.
研究者
相似试验
已完成
不适用
Protecting against brain damage by improving treatment in neonates with hypoglycemia.E16.2Hypoglycaemia, unspecifiedDRKS00024086Heinrich-Heine Universität957
已完成
不适用
Schizophrenia Termination Of Pharmacotherapy: STOP-trialSchizophrenia, schizophreniform disorder, schizoaffective disorderMental and Behavioural DisordersSchizophreniaISRCTN06332944The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)20
暂停
不适用
Schizophrenia Termination Of Pharmacotherapy-STOP-trial.Schizophrenic disorders:SchizophreniaSchizophreniform disorderSchizoaffective disorderNL-OMON26866Divisie Hersenen20
进行中(未招募)
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000
进行中(未招募)
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ATInstitut de Recherches Internationales Servier18,000
